Immune Tolerance Network (UM1 Clinical Trial Required)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Oct 20, 2026Closes
Jan 29, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), City or township governments, Public housing authorities/Indian housing authorities, Small businesses, State governments, Native American tribal governments (Federally recognized), Special district governments, County governments, Private institutions of higher education, For profit organizations other than small businesses, Independent school districts, Others (see text field entitled "Additional Information on Eligibility" for clarification), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Description
The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.